RESEARCH TRIANGLE PARK, N.C. & MADISON, Wis.--(BUSINESS WIRE)--Metabolon, Inc. and Stemina Biomarker Discovery, Inc. have entered into a licensing agreement and dismissed the patent litigation which was pending in the United States District Court, Western District of Wisconsin. Terms of the licensing agreement have not been released.
Elizabeth Donley, Chief Executive Officer of Stemina, said “We are happy to have reached an agreement with Metabolon and to have settled our differences in a way that allows both companies to move forward.” Donley stated she is focused on ongoing autism studies and raising money to accelerate the pace to market for Stemina’s blood test for autism as well as putting the final details together on a large contract with the United States Environmental Protection Agency.
“We are pleased to reach an agreement that brings our pending litigation to an end and further underscores the significant value of Metabolon's technological innovations and Intellectual Property," said John Ryals, CEO and President of Metabolon. Ryals continued, “Our focus continues to be the needs of our collaborators and the advancement of the metabolomics science for biomarker discovery, to uncover solutions in medical and nutritional research and the life sciences.”
Stemina Biomarker Discovery was founded in 2007 and is located in the Madison, Wisconsin. Stemina is a biomarker discovery company using its proprietary metabolomics platform to identify changes in metabolism which can be used to develop and commercialize tests to improve drug and chemical safety and human health. Stemina’s operates its business in two divisions: one focused on developing diagnostic tests beginning with a blood test for diagnosing autism; and the other on compound safety screening for pharmaceutical, chemical and consumer products companies, the US Army and the Environmental Protection Agency. Visit Stemina on the web at www.stemina.com.
Metabolon, Inc. is the world leader in the field of metabolomics by pioneering and patenting the industry’s leading biochemical biomarker discovery and profiling platform. It has developed the technology to quickly identify and measure the biochemicals in a biological sample through its proprietary global processing method. Quantose™ is the first diagnostic test discovered by Metabolon using its technology. Metabolon has a broad pipeline of diagnostic products in the fields of obesity-related conditions and cancer. Metabolon’s technology expertise is being embraced by a wide range of pharmaceutical, biotechnology, food and agricultural companies. Metabolytics, its biomarker discovery and analysis business, has completed over 3,000 client studies with more than 550 customers. For more information about Metabolon, please contact Matt Zaske at firstname.lastname@example.org 919-595-2200 or visit www.metabolon.com.